Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

被引:12
|
作者
Suleiman, Ahmed Abbas [1 ]
Frechen, Sebastian [1 ]
Scheffler, Matthias [2 ]
Zander, Thomas [2 ]
Kahraman, Deniz [3 ]
Kobe, Carsten [3 ]
Wolf, JRgen [2 ]
Nogova, Lucia [2 ]
Fuhr, Uwe [1 ]
机构
[1] Univ Hosp Cologne, Dept Pharmacol, Clin Pharmacol Unit, D-50931 Cologne, Germany
[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, D-50931 Cologne, Germany
[3] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Nucl Med, D-50931 Cologne, Germany
关键词
Modeling; NSCLC; PET; Survival; Erlotinib; POSITRON-EMISSION-TOMOGRAPHY; PHASE-II; SIZE; PET; OPPORTUNITIES; PREDICTION; ONCOLOGY; EVALUATE; DESIGN; RECIST;
D O I
10.1097/JTO.0000000000000330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Pharmacostatistical models can quantify different relationships and improve decision making in personalized medicine and drug development. Our objectives were to develop models describing non-small-cell lung cancer (NSCLC) dynamics during first-line treatment with erlotinib, and survival of the cohort. Methods: Data from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. Exposure-driven disease-drug models were built to describe tumor metabolic and proliferative dynamics evaluated by positron emission tomography (PET) using 2'-deoxy-2'-[F-18] fluoro-D-glucose (FDG) and 3'-[F-18] fluoro-3'-deoxy-L-thymidine (FLT), respectively, at baseline, weeks 1 and 6 after starting erlotinib treatment. A parametric time-to-event model was built to describe overall survival (OS). Demographics, histology, mutational, smoking, and baseline performance statuses were tested for their effects on models developed, in addition to tumor dynamics on survival. Results: An exponential relationship described progression, and a concentration-driven drug effect model described erlotinib effect. An activating epidermal growth factor receptor (EGFR) mutation increased the drug effect as assessed using FDG-PET by 2.19-fold (95% confidence interval [CI]: 1.35-4.44). An exponential distribution described the times-to-death distribution. Baseline FDG uptake (p=0.0005; hazard ratio [HR] = 1.26 for every unit increase, 95% CI: 1.13-1.42) and relative change in FDG uptake after 1 week of treatment (p=0.0073; HR=0.84 for every 10% drop, 95% CI: 0.71-0.91) were significant OS predictors irrespective of the EGFR mutational status. FLT-PET was statistically less significant than FDG-PET for OS prediction. Conclusion: Models describing tumor dynamics and survival of advanced NSCLC patients first-treated with erlotinib were developed. The impacts of different covariates were quantified.
引用
收藏
页码:84 / 92
页数:9
相关论文
共 50 条
  • [1] Overall survival benefit in advanced non-small-cell lung cancer
    Owen, Olwen Glynn
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 379 - 379
  • [2] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    [J]. ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [3] Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer
    Presley, Carolyn J.
    Tang, Joy
    Benedict, Jason
    Grogan, Madison
    Reisinger, Sarah
    Janse, Sarah
    Wong, Melisa L.
    Arrato, Nicole A.
    Davenport, Ashley
    Shields, Peter G.
    Andersen, Barbara L.
    [J]. LUNG CANCER, 2024, 196
  • [4] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 123 - 132
  • [5] Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    Pérez-Soler, R
    Chachoua, A
    Hammond, LA
    Rowinsky, EK
    Huberman, M
    Karp, D
    Rigas, J
    Clark, GM
    Santabàrbara, P
    Bonomi, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3238 - 3247
  • [6] Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
    Justin Jee
    Emily S. Lebow
    Randy Yeh
    Jeeban P. Das
    Azadeh Namakydoust
    Paul K. Paik
    Jamie E. Chaft
    Gowtham Jayakumaran
    A. Rose Brannon
    Ryma Benayed
    Ahmet Zehir
    Mark Donoghue
    Nikolaus Schultz
    Debyani Chakravarty
    Ritika Kundra
    Ramyasree Madupuri
    Yonina R. Murciano-Goroff
    Hai-Yan Tu
    Chong-Rui Xu
    Andrés Martinez
    Clare Wilhelm
    Jesse Galle
    Bobby Daly
    Helena A. Yu
    Michael Offin
    Matthew D. Hellmann
    Piro Lito
    Kathryn C. Arbour
    Marjorie G. Zauderer
    Mark G. Kris
    Kenneth K. Ng
    Juliana Eng
    Isabel Preeshagul
    W. Victoria Lai
    John J. Fiore
    Afsheen Iqbal
    Daniela Molena
    Gaetano Rocco
    Bernard J. Park
    Lee P. Lim
    Mark Li
    Candace Tong-Li
    Madhawa De Silva
    David L. Chan
    Connie I. Diakos
    Malinda Itchins
    Stephen Clarke
    Nick Pavlakis
    Adrian Lee
    Natasha Rekhtman
    [J]. Nature Medicine, 2022, 28 : 2353 - 2363
  • [7] Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
    Jee, Justin
    Lebow, Emily S.
    Yeh, Randy
    Das, Jeeban P.
    Namakydoust, Azadeh
    Paik, Paul K.
    Chaft, Jamie E.
    Jayakumaran, Gowtham
    Brannon, A. Rose
    Benayed, Ryma
    Zehir, Ahmet
    Donoghue, Mark
    Schultz, Nikolaus
    Chakravarty, Debyani
    Kundra, Ritika
    Madupuri, Ramyasree
    Murciano-Goroff, Yonina R.
    Tu, Hai-Yan
    Xu, Chong-Rui
    Martinez, Andres
    Wilhelm, Clare
    Galle, Jesse
    Daly, Bobby
    Yu, Helena A.
    Offin, Michael
    Hellmann, Matthew D.
    Lito, Piro
    Arbour, Kathryn C.
    Zauderer, Marjorie G.
    Kris, Mark G.
    Ng, Kenneth K.
    Eng, Juliana
    Preeshagul, Isabel
    Lai, W. Victoria
    Fiore, John J.
    Iqbal, Afsheen
    Molena, Daniela
    Rocco, Gaetano
    Park, Bernard J.
    Lim, Lee P.
    Li, Mark
    Tong-Li, Candace
    De Silva, Madhawa
    Chan, David L.
    Diakos, Connie, I
    Itchins, Malinda
    Clarke, Stephen
    Pavlakis, Nick
    Lee, Adrian
    Rekhtman, Natasha
    [J]. NATURE MEDICINE, 2022, 28 (11) : 2353 - +
  • [8] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
  • [9] Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer.
    Ersek, Jennifer L.
    Symanowski, James Thomas
    Kim, Edward S.
    Adams, Swann Arp
    Hebert, James R.
    Eberth, Jan Marie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zheng-Tao Zhou
    Xin-Hua Xu
    Qing Wei
    Ming-qian Lu
    Jie Wang
    Cai-Hong Wen
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127